$15.66
In the last 1 year, Novo Nordisk A/s has given 82.6% return, outperforming this stock by 90.1%
0.96%
Downside
Day's Volatility :3.66%
Upside
2.73%
68.9%
Downside
52 Weeks Volatility :76.85%
Upside
25.57%
Period | An2 Therapeutics, Inc. | Index (Russel 2000) |
---|---|---|
3 Months | 92.34% | 0.0% |
6 Months | 62.26% | -1.9% |
1 Year | -13.08% | 6.3% |
3 Years | 4.42% | 14.9% |
Market Capitalization | 453.0M |
Book Value | $4.0 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.49 |
Wall Street Target Price | 24.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -32.48% |
Return On Equity TTM | -53.34% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -3.49 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.36 |
EPS Estimate Next Year | -3.45 |
EPS Estimate Current Quarter | -0.85 |
EPS Estimate Next Quarter | -0.92 |
What analysts predicted
Upside of 53.26%
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() An2 Therapeutics, Inc. | 7.92% | 62.26% | -13.08% | 4.42% | 4.42% |
![]() Moderna, Inc. | -5.55% | -35.23% | -14.63% | 50.11% | 455.32% |
![]() Regeneron Pharmaceuticals, Inc. | 0.01% | -0.39% | 11.95% | 45.71% | 105.45% |
![]() Novo Nordisk A/s | -4.33% | 13.96% | 77.36% | 164.9% | 284.93% |
![]() Seagen, Inc. | 2.4% | 5.02% | 54.07% | 9.88% | 161.08% |
![]() Vertex Pharmaceuticals Incorporated | -0.15% | 9.93% | 16.91% | 33.34% | 81.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() An2 Therapeutics, Inc. | NA | NA | NA | -3.36 | -0.53 | -0.32 | 0.0 | 4.0 |
![]() Moderna, Inc. | 34.94 | 34.94 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 22.08 | 22.08 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 43.05 | 43.05 | 2.03 | 1.64 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.67 | 26.67 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() An2 Therapeutics, Inc. | Buy | $453.0M | 4.42% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $38.2B | 455.32% | 34.94 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.6B | 105.45% | 22.08 | 33.93% |
![]() Novo Nordisk A/s | Buy | $412.6B | 284.93% | 43.05 | 33.4% |
![]() Seagen, Inc. | Hold | $39.8B | 161.08% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $89.7B | 81.18% | 26.67 | 35.4% |
RA Capital Management, LLC
Bvf Inc
Citadel Advisors Llc
TCG Crossover Management, LLC
HHG PLC
Octagon Capital Advisors LP
an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.
Organization | An2 Therapeutics, Inc. |
Employees | 35 |
CEO | Mr. Joseph S. Zakrzewski |
Industry | Services |
H&e Equipment Services Inc
$15.66
-2.61%
Destination Xl Group Inc
$15.66
-2.61%
Tilly's Inc
$15.66
-2.61%
Barrett Business Services Inc
$15.66
-2.61%
Healthcare Services Group Inc
$15.66
-2.61%
Bristow Group Inc
$15.66
-2.61%
Rumbleon Inc
$15.66
-2.61%
Carrols Restaurant Group Inc
$15.66
-2.61%
Jianzhi Education Technology Group Company Ltd.
$15.66
-2.61%